Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. - Wikidata - wikimedia - TriplyDB

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

http://www.wikidata.org/entity/Q35332246

about

Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials Clinical Trials in Branch Retinal Vein Occlusion Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept Strategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study.EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.[Retinal vein occlusion: Therapy of retinal vein occlusion].Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials.Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves.Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment.Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab.Metamorphopsia Associated with Branch Retinal Vein Occlusion Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2.Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice.Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusion Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis.Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion.Association between retinal hemorrhagic pattern and macular perfusion status in eyes with acute branch retinal vein occlusion.Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion.The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary.Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series.Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion.Anti-angiogenic Therapy for Retinal Disease.Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab.SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.

P2860

Q26750459-919406F0-7881-45CB-A7F5-5C1C2CFCA3E9 Q26767092-0C118F32-DC25-4178-9380-D3C934AEE47B Q26799492-D0ECB206-B4AE-4854-9396-B8E17C2929C2 Q28075557-91155D50-4578-4F81-BC14-1613490EC5AF Q30391349-7075CDF2-9D1C-4EAC-A0C4-335EE9DD9A4A Q30490419-80CD876C-06BD-40F4-8007-DB83C0113E3E Q31155420-CF9D07D5-4754-4536-B5F6-E5B0C8F4E55D Q34518374-82C29A32-4B5D-49A8-9295-921395991FE5 Q35655005-038EF4BB-F2F5-4949-BB59-3D8EAF9350A3 Q35737854-299D0D04-6711-4DDE-AD50-534A19E04129 Q35769968-225E2865-D102-40B8-BC9E-E3EA15A6216D Q35882307-76F300D4-6C27-4724-A93F-88C81DC118C5 Q35902075-6AE5592E-EFB2-4735-9A1E-2E8800AB32DB Q35988002-E054BB4C-D70C-450F-8DE9-1A74CF1BC95D Q36001663-24B8C0D0-C175-4F92-AE09-23B2D0B169B0 Q36058492-A2985188-A8F2-4ED6-B923-0DEBC60B34D1 Q36099741-46DF482D-DC22-42FE-9E82-BAFC55A3222F Q36127283-FDB56452-19EB-4D58-8279-B4CA97717F18 Q36200924-2D5BA548-AA0D-4E4D-8641-2A7620B7FCDC Q36296091-DD92D768-3D92-4390-9239-D565C2D9BF9C Q36331045-C9A7D6DC-2439-44E2-BDCD-7CC5A0AAF3D8 Q36357723-99E6FC84-1DA3-4CE2-99AA-6FFDEEEC7EDA Q36412013-FDED45FE-40E4-47E4-9CD3-136830A3CC46 Q36526922-C54A6DCE-3906-425D-960D-DB0E66C2457A Q36835209-F0A81C4A-DA00-4ABC-B134-D296A4D71EE6 Q37030777-0D327120-7D56-4025-9B1B-EBF88E934C9D Q37288622-E3365F26-C192-4411-8259-462751E5F8FD Q37457117-46EF2BAC-5036-4F35-B73D-B9B0FDD41286 Q37530866-8E000F52-808E-461C-90D1-79D02BDAB2AF Q37669520-8FFB0812-729E-4D27-9D3E-987DBB65871F Q38805247-917C0FD1-6E86-4F99-88D0-7D49826C908D Q41371210-EDEE3D22-83DE-4387-A6D5-DFD7893E1467 Q41767272-1BE4A891-04C5-42F4-BA98-C5AB78232442 Q46777540-3291246D-299E-41EF-9FFC-D3445E814997 Q48352897-D1782293-D6FD-4EE2-BE35-3F7C40DB6D78 Q49619345-7C2B741D-F987-472A-A213-503B7F1D219E Q50062366-08B9B05F-8586-40EE-9526-C89C5B634DDD Q50859000-72E52258-EEED-4303-9A33-10EE717733B3 Q53199049-16383A38-31D4-4521-9969-8A25D8BC63F0 Q55073223-DE64C225-9A81-4BFE-A18C-94D8DD3ADDCA

P2860

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

http://www.wikidata.org/entity/Q35332246

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@ast

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@en

type

label

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@ast

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@en

prefLabel

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@ast

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@en

P1433

Q35332246-142EC65F-B2F9-421D-B519-96A8149FDFF6

P1476

Q35332246-8C4501E2-842D-465A-B46D-1B10563816CC

P2093

Q35332246-046B174B-CF40-4205-8612-BEBA98F3FEBC

Q35332246-18BA648C-63DA-4C17-9314-4E2A2CF481E5

Q35332246-2E56C9B3-5A8C-4F14-BAFE-1F02F6D7F669

Q35332246-37B62413-CF55-40B6-84A2-227469E9238C

Q35332246-7280C142-223F-4283-A759-0A5529AB749B

Q35332246-A3DED6A1-9985-471F-AAD3-2FF782C9B950

Q35332246-ACD85A2E-715C-4D39-B1B7-C54B4438FA6D

Q35332246-CB9DDB85-2FA0-44C2-BD49-907038184DC9

Q35332246-D1122BDB-198D-4C97-91BE-508EA811FF70

Q35332246-D1301B69-C294-4D99-8795-DEA33BA8102E

P304

Q35332246-506FD4CC-E931-4DDC-8A2A-82F2EAE7C9F2

P31

Q35332246-96BB2F92-73E2-429E-98C0-F213390D62DB

P356

Q35332246-2A82393D-6021-4A36-AA25-12744A0F4D26

P433

Q35332246-A67BEB59-E3C4-402A-962C-B31689536823

P478

Q35332246-5D666C6D-1C9E-4458-BD32-5D88E997F632

P577

Q35332246-8E017DB4-98FB-4218-B303-F8AE1F678E0B

P698

Q35332246-D05E786D-5306-4FE4-BEAE-3461EAFC6F10

P356

J.OPHTHA.2014.08.031

P1433

P1476

Intravitreal aflibercept for m ...... results of the VIBRANT study.

@en

P2093

Alyson J Berliner

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

David S Boyer

http://www.w3.org/2001/XMLSchema#string

Husain Kazmi

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Heier

http://www.w3.org/2001/XMLSchema#string

Julia A Haller

http://www.w3.org/2001/XMLSchema#string

Karen W Chu

http://www.w3.org/2001/XMLSchema#string

Kristine Erickson

http://www.w3.org/2001/XMLSchema#string

Peter A Campochiaro

http://www.w3.org/2001/XMLSchema#string

Robert Vitti

http://www.w3.org/2001/XMLSchema#string

P304

538-544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2014.08.031

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25315663

http://www.w3.org/2001/XMLSchema#string